

Project Cell penetrating miRNA-based therapy for acute myocardial infarction

StemMeditech Inc.



CARDIOVASCULAR	Candidate
Product Type	RNA-antagomir
Indication	Acute myocardial infarction
Target	miRNA
MoA(Mechanism of Action)	Inhibit/enhance miRNAs for stemness control
Competitiveness	<p>First in class/best in class(rodent model for ischemic reperfusion)</p> <ul style="list-style-type: none"> * 3 times increase of cardiac output * 6 times increase of capillary density in infarct region * 7 times increase of viable cardiomyocyte <p>Easy production, application</p> <ul style="list-style-type: none"> * transient action, no biological burden • High effect/low cost • Ready for global supply with consistent CMC
Development Stage	Candidate
Route of Administration	Myocardium inj- coronary artery injection (plan)